MedPath

Merck, Inc.

🇵🇭Philippines
Ownership
Subsidiary
Employees
-
Market Cap
$295.3B
Website
http://www.merck.ph
Clinical Trials
Related News

High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)

Phase 1
Completed
Conditions
Melanoma
Interventions
Drug: PEG-Intron
First Posted Date
2007-04-06
Last Posted Date
2017-06-07
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
32
Registration Number
NCT00457418

Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)

Phase 2
Completed
Conditions
Soft Tissue Infections
Urinary Tract Infections
Bacterial Pneumonia
First Posted Date
2007-03-23
Last Posted Date
2017-02-17
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
400
Registration Number
NCT00451386

Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)

Phase 3
Completed
Conditions
Anesthesia, General
Interventions
Drug: Sugammadex
Drug: neostigmine
First Posted Date
2007-03-23
Last Posted Date
2019-11-15
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
84
Registration Number
NCT00451100

Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)

Phase 3
Completed
Conditions
Anesthesia, General
Interventions
Drug: Sugammadex
Drug: Neostigmine
First Posted Date
2007-03-23
Last Posted Date
2019-03-04
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
198
Registration Number
NCT00451217

MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)

Phase 3
Completed
Conditions
Glaucoma
Interventions
Drug: dorzolamide hydrochloride (+) timolol maleate
First Posted Date
2007-03-21
Last Posted Date
2017-06-20
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
474
Registration Number
NCT00449956

Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049)

Phase 3
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: sitagliptin phosphate
First Posted Date
2007-03-21
Last Posted Date
2017-05-11
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1050
Registration Number
NCT00449930

ZOSTAVAX(R) Local Registration Trial (V211-019)

Phase 3
Completed
Conditions
Varicella Virus Infection
Interventions
Biological: Zoster Vaccine, Live, (Oka-Merck)
First Posted Date
2007-03-08
Last Posted Date
2015-06-04
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
150
Registration Number
NCT00444860

A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

Phase 4
Completed
Conditions
Infection
Pneumonia
First Posted Date
2007-03-08
Last Posted Date
2017-02-17
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
120
Registration Number
NCT00445094

Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma

Phase 1
Completed
Conditions
Ocular Hypertension
Open Angle Glaucoma
Interventions
Drug: Placebo
Drug: INS115644 Ophthalmic Solution
First Posted Date
2007-03-07
Last Posted Date
2015-01-21
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
56
Registration Number
NCT00443924

MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)

Phase 3
Terminated
Conditions
HIV Infection
Interventions
Drug: MK0518 (raltegravir)
First Posted Date
2007-03-06
Last Posted Date
2017-03-21
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
352
Registration Number
NCT00443703
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy